MarketCapExport financials
VBI Vaccines (VBIV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
VBI Vaccines Financial Ratios 2023-2011 | VBIV
Brief overview of VBI Vaccines 's valuation multiples
The comparison uses the five latest available annual observations between 2019 and 2023.
The current valuation set is EV/EBITDA 0.18x (median 0.46x), P/S 1.11x (median 85.93x), P/B 0.11x (median 1.87x). The current ratio basket stands about 77.4% below the five-year comparison base. Earnings and risk trends should explain the discount.
The latest available business-quality ratios are ROE -12.3%, ROA -106.8%, ROCE -7.1%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
The cash conversion cycle lengthened from -98.9 days to 2 days, or 100.8 days. More cash is tied up in operations.
Overall assessment
VBI Vaccines 's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios VBI Vaccines
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.8 | -8.6 | -13.0 | -3.0 | -1.7 | -4.8 | -0.0 | -2.5 | -9.3 | -9.1 | -2.0 | -8.5 |
P/S |
1.1 | 85.9 | 945.4 | 565.7 | 74.2 | 31.3 | 938.1 | 0.8 | 68.8 | - | - | - | - |
EPS |
-6.0 | -0.4 | -0.3 | -0.2 | -0.5 | -1.0 | -0.9 | -0.2 | -2.1 | - | - | - | - |
EV (Enterprise Value) |
-14 M | 30.3 M | 475 M | 544 M | 155 M | 85.2 M | 147 M | -11.1 M | 53.5 M | 42.6 M | 60.6 M | 27.7 M | 210 M |
EBITDA per Share |
-5 | -0.31 | -0.26 | -0.19 | -0.43 | -0.91 | -0.83 | -649 | -1.84 | -1.06 | -1.47 | -2.8 | -8.92 |
EV/EBITDA |
0.2 | -0.4 | -7.2 | -13.0 | -3.0 | -1.4 | -4.0 | 0.5 | -2.3 | -1.0 | -1.6 | 0.8 | -8.0 |
PEG |
-0.0 | 0.1 | 0.26 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | 0.0 | -1.17 | -0.16 | -0.03 | 0.0 |
P/B |
0.1 | 0.6 | 2.8 | 3.5 | 1.9 | 1.1 | 1.6 | 0.0 | 3.9 | 0.3 | 0.3 | 0.1 | 1.0 |
P/CF |
-0.2 | -1.3 | -14.9 | -12.8 | -3.4 | -2.3 | -6.0 | -0.0 | -7.2 | -6.2 | -7.1 | -1.9 | -18.1 |
ROE % |
-1233.37 | -176.59 | -48.48 | -26.92 | -62.11 | -64.81 | -32.55 | -10.05 | -214.80 | -2.93 | -3.79 | -7.13 | -11.92 |
ROA % |
-106.77 | -73.06 | -33.17 | -22.08 | -44.85 | -46.22 | -26.77 | -8.03 | -153.67 | -2.92 | -3.79 | -7.10 | -9.08 |
ROCE % |
-712.54 | -69.25 | -38.29 | -22.71 | -56.68 | -52.88 | -28.15 | -25.58 | -168.31 | -3.37 | -4.21 | -7.38 | -8.49 |
Current Ratio |
- | - | - | 5.6 | 3.6 | 3.5 | 5.6 | 5.0 | 61.6 | 151.9 | 202.3 | 82.9 | 23.8 |
DSO |
2.0 | 17.2 | 24.6 | 47.8 | 21.1 | 10.8 | 138.9 | 137.2 | 17.8 | - | - | - | - |
DIO |
- | - | - | 64.2 | 45.9 | 68.8 | 56.9 | 106.7 | 64.0 | - | - | - | - |
DPO |
- | - | - | 96.8 | 165.8 | 318.3 | 134.5 | 120.6 | 19.8 | - | 12.6 | 13.1 | - |
Operating Cycle |
2.0 | 17.2 | 24.6 | 112.1 | 67.0 | 79.6 | 195.8 | 243.9 | 81.8 | - | - | - | - |
Cash Conversion Cycle |
2.0 | 17.2 | 24.6 | 15.3 | -98.9 | -238.7 | 61.2 | 123.3 | 61.9 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios VBI Vaccines
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.73 | - | -1.01 | -5.18 | -3.22 | - | -0.1 | -0.18 | -0.08 | - | -0.06 | -0.07 | -0.07 | - | -0.06 | -0.04 | -0.05 | - | -0.15 | -0.13 | -0.15 | - | -0.24 | -0.26 | -0.19 | -0.2 | -0.24 | -0.22 | -0.22 | -0.23 | -0.2 | -0.2 | -0.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.46 | - | -0.4 | -4.18 | -2.21 | - | -0.08 | -0.08 | -0.06 | - | -0.05 | -0.06 | -0.06 | - | -0.05 | -0.03 | -0.05 | - | -0.15 | -0.12 | -0.14 | - | -0.22 | -0.24 | -0.18 | - | -0.21 | -0.2 | -0.22 | - | -214 | -0.44 | -0.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-347.76 | -675.18 | -705.26 | -645.74 | -151.41 | -89.77 | -99.67 | -79.99 | -46.50 | -30.10 | -37.93 | -35.55 | -36.38 | -26.58 | -43.21 | -52.64 | -61.97 | -50.74 | -70.67 | -72.68 | -66.92 | -50.07 | -59.70 | -55.34 | -49.70 | -49.58 | -49.99 | -43.14 | -37.81 | -10.05 | - | -8.72 | -7.66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-116.14 | -92.42 | -107.07 | -113.33 | -73.76 | -52.16 | -59.22 | -52.35 | -33.72 | -22.76 | -29.28 | -28.11 | -28.13 | -20.21 | -32.46 | -37.43 | -43.10 | -35.31 | -49.43 | -51.16 | -48.76 | -37.19 | -45.11 | -42.07 | -37.89 | -37.71 | -37.81 | -33.70 | -30.03 | -8.03 | - | -6.97 | -6.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
422.98 | -123.37 | -139.07 | -113.79 | -62.78 | -43.05 | -50.90 | -43.48 | -33.97 | -24.02 | -30.41 | -28.13 | -31.90 | -24.01 | -39.91 | -48.84 | -56.65 | -44.60 | -60.75 | -60.08 | -54.54 | -41.15 | -53.20 | -47.12 | -41.81 | -32.03 | -48.69 | -45.34 | -9.92 | - | - | -16.66 | -8.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
8.5 | - | 3.0 | 22.8 | 35.3 | - | 38.4 | 31.2 | 39.8 | - | 53.7 | 84.2 | 37.7 | - | 7.5 | 38.7 | 36.8 | - | 17.6 | 12.3 | 21.9 | - | 52.1 | 66.1 | 79.5 | 78.5 | 101.4 | 35.7 | 19.0 | 3.3 | 1.6 | 3.2 | 57.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.0 | 43.7 | 30.4 | - | 60.4 | 44.2 | 92.1 | - | 122.2 | 77.3 | 50.7 | - | 54.6 | 62.3 | 64.0 | - | 25.2 | 29.3 | 90.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 124.2 | 82.1 | 43.2 | - | 148.2 | 172.3 | 540.7 | - | 429.2 | 237.9 | 140.4 | - | 198.3 | 128.9 | 125.2 | - | 61.3 | 71.3 | 102.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 3.0 | 22.8 | 35.3 | - | 38.4 | 31.2 | 39.8 | - | 53.7 | 84.2 | 37.7 | - | 116.6 | 133.5 | 87.7 | - | 78.0 | 70.3 | 109.4 | - | 123.5 | 99.8 | 105.9 | 64.9 | 121.5 | 90.9 | 112.9 | 3.3 | 26.9 | 32.6 | 148.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 3.0 | 22.8 | 35.3 | - | 38.4 | 31.2 | 39.8 | - | 53.7 | 84.2 | 37.7 | - | -44.8 | -31.9 | 1.6 | - | 25.9 | 26.6 | -168.5 | - | -566.3 | -418.1 | -148.1 | 64.9 | -2.3 | -30.8 | -24.1 | 3.3 | -34.5 | -38.8 | 45.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company VBI Vaccines , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Israel
Germany
Australia
Britain
Russia
China
France
Belgium
Canada
